Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 91.46
EXAS's Cash to Debt is ranked higher than
70% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.06 vs. EXAS: 91.46 )
Ranked among companies with meaningful Cash to Debt only.
EXAS' s Cash to Debt Range Over the Past 10 Years
Min: 12.24  Med: 10000.00 Max: No Debt
Current: 91.46
Equity to Asset 0.92
EXAS's Equity to Asset is ranked higher than
96% of the 183 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.61 vs. EXAS: 0.92 )
Ranked among companies with meaningful Equity to Asset only.
EXAS' s Equity to Asset Range Over the Past 10 Years
Min: -0.41  Med: 0.69 Max: 0.96
Current: 0.92
-0.41
0.96
F-Score: 3
Z-Score: 9.53
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -570.23
EXAS's Operating margin (%) is ranked lower than
86% of the 187 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.66 vs. EXAS: -570.23 )
Ranked among companies with meaningful Operating margin (%) only.
EXAS' s Operating margin (%) Range Over the Past 10 Years
Min: -5591.71  Med: -402.79 Max: 1150.29
Current: -570.23
-5591.71
1150.29
Net-margin (%) -566.55
EXAS's Net-margin (%) is ranked lower than
87% of the 187 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.98 vs. EXAS: -566.55 )
Ranked among companies with meaningful Net-margin (%) only.
EXAS' s Net-margin (%) Range Over the Past 10 Years
Min: -5564.4  Med: -374.56 Max: 1123.53
Current: -566.55
-5564.4
1123.53
ROE (%) -55.72
EXAS's ROE (%) is ranked lower than
76% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.39 vs. EXAS: -55.72 )
Ranked among companies with meaningful ROE (%) only.
EXAS' s ROE (%) Range Over the Past 10 Years
Min: -505.37  Med: -52.37 Max: -26.92
Current: -55.72
-505.37
-26.92
ROA (%) -51.03
EXAS's ROA (%) is ranked lower than
76% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -4.60 vs. EXAS: -51.03 )
Ranked among companies with meaningful ROA (%) only.
EXAS' s ROA (%) Range Over the Past 10 Years
Min: -95.07  Med: -42.77 Max: -18.9
Current: -51.03
-95.07
-18.9
ROC (Joel Greenblatt) (%) -630.48
EXAS's ROC (Joel Greenblatt) (%) is ranked lower than
81% of the 194 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -3.03 vs. EXAS: -630.48 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
EXAS' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -3463.3  Med: -1718.22 Max: -637.37
Current: -630.48
-3463.3
-637.37
Revenue Growth (3Y)(%) -37.00
EXAS's Revenue Growth (3Y)(%) is ranked lower than
91% of the 118 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.70 vs. EXAS: -37.00 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
EXAS' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -22.55 Max: 47.4
Current: -37
0
47.4
EBITDA Growth (3Y)(%) 30.50
EXAS's EBITDA Growth (3Y)(%) is ranked higher than
90% of the 99 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.90 vs. EXAS: 30.50 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
EXAS' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -39.4  Med: -14.35 Max: 45.4
Current: 30.5
-39.4
45.4
EPS Growth (3Y)(%) 31.70
EXAS's EPS Growth (3Y)(%) is ranked higher than
88% of the 110 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.10 vs. EXAS: 31.70 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
EXAS' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -43.1  Med: -16.15 Max: 46.9
Current: 31.7
-43.1
46.9
» EXAS's 10-Y Financials

Financials (Next Earnings Date: 2016-02-24)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2015

EXAS Guru Trades in Q1 2015

PRIMECAP Management 2,526,300 sh (+0.20%)
Paul Tudor Jones Sold Out
Steven Cohen 158,900 sh (-93.60%)
» More
Q2 2015

EXAS Guru Trades in Q2 2015

PRIMECAP Management 2,631,300 sh (+4.16%)
Steven Cohen 74,400 sh (-53.18%)
» More
Q3 2015

EXAS Guru Trades in Q3 2015

PRIMECAP Management 2,736,300 sh (+3.99%)
Steven Cohen 12,000 sh (-83.87%)
» More
Q4 2015

EXAS Guru Trades in Q4 2015

Jim Simons 12,160 sh (New)
PRIMECAP Management 3,096,300 sh (+13.16%)
» More
» Details

Insider Trades

Latest Guru Trades with EXAS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Exact Sciences Corp

Meridian Funds Comments on Exact Sciences Corp - Jun 20, 2014

Exact Sciences Corp. (EXAS) also had negative returns during the period, which created a drag on overall Fund performance. Exact Sciences is an early stage diagnostic company with a test for early detection of colorectal cancers. Upon receipt of the U.S. Food and Drug Administration’s approval, we believe that Exact Sciences’s Cologuard test will help revolutionize colorectal screening and increase overall compliance rates with clinical guidelines. We think that the large market, combined with attractive unit economics, should drive an improvement in shareholder value.



From Meridian Funds's semi-annual report ended December 31, 2013.



Check out Meridian Funds latest stock trades

Ratios

vs
industry
vs
history
P/B 1.59
EXAS's P/B is ranked higher than
71% of the 241 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.78 vs. EXAS: 1.59 )
Ranked among companies with meaningful P/B only.
EXAS' s P/B Range Over the Past 10 Years
Min: 1.49  Med: 6.48 Max: 37
Current: 1.59
1.49
37
P/S 19.75
EXAS's P/S is ranked lower than
99.99% of the 241 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.10 vs. EXAS: 19.75 )
Ranked among companies with meaningful P/S only.
EXAS' s P/S Range Over the Past 10 Years
Min: 8.84  Med: 49.45 Max: 2482
Current: 19.75
8.84
2482
Current Ratio 15.28
EXAS's Current Ratio is ranked higher than
95% of the 191 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.68 vs. EXAS: 15.28 )
Ranked among companies with meaningful Current Ratio only.
EXAS' s Current Ratio Range Over the Past 10 Years
Min: 1.02  Med: 8.48 Max: 50.84
Current: 15.28
1.02
50.84
Quick Ratio 15.03
EXAS's Quick Ratio is ranked higher than
95% of the 191 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.41 vs. EXAS: 15.03 )
Ranked among companies with meaningful Quick Ratio only.
EXAS' s Quick Ratio Range Over the Past 10 Years
Min: 1.02  Med: 8.48 Max: 50.84
Current: 15.03
1.02
50.84
Days Inventory 88.26
EXAS's Days Inventory is ranked higher than
50% of the 153 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 88.26 vs. EXAS: 88.26 )
Ranked among companies with meaningful Days Inventory only.
EXAS' s Days Inventory Range Over the Past 10 Years
Min: 169.5  Med: 169.50 Max: 169.5
Current: 88.26
Days Sales Outstanding 57.93
EXAS's Days Sales Outstanding is ranked higher than
58% of the 155 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 65.71 vs. EXAS: 57.93 )
Ranked among companies with meaningful Days Sales Outstanding only.
EXAS' s Days Sales Outstanding Range Over the Past 10 Years
Min: 279.33  Med: 279.33 Max: 279.33
Current: 57.93
Days Payable 27.11
EXAS's Days Payable is ranked lower than
79% of the 149 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 52.88 vs. EXAS: 27.11 )
Ranked among companies with meaningful Days Payable only.
EXAS' s Days Payable Range Over the Past 10 Years
Min: 71.29  Med: 1565.28 Max: 249295
Current: 27.11
71.29
249295

Valuation & Return

vs
industry
vs
history
Price/Net Cash 1.82
EXAS's Price/Net Cash is ranked higher than
86% of the 100 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.81 vs. EXAS: 1.82 )
Ranked among companies with meaningful Price/Net Cash only.
EXAS' s Price/Net Cash Range Over the Past 10 Years
Min: 2.02  Med: 6.67 Max: 90
Current: 1.82
2.02
90
Price/Net Current Asset Value 1.73
EXAS's Price/Net Current Asset Value is ranked higher than
86% of the 170 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.61 vs. EXAS: 1.73 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
EXAS' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 1.98  Med: 6.57 Max: 60
Current: 1.73
1.98
60
Price/Tangible Book 1.57
EXAS's Price/Tangible Book is ranked higher than
79% of the 218 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.79 vs. EXAS: 1.57 )
Ranked among companies with meaningful Price/Tangible Book only.
EXAS' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.88  Med: 6.22 Max: 34.23
Current: 1.57
1.88
34.23
Price/Median PS Value 0.41
EXAS's Price/Median PS Value is ranked higher than
85% of the 240 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.94 vs. EXAS: 0.41 )
Ranked among companies with meaningful Price/Median PS Value only.
EXAS' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.22  Med: 1.36 Max: 38.76
Current: 0.41
0.22
38.76
Earnings Yield (Greenblatt) (%) -65.97
EXAS's Earnings Yield (Greenblatt) (%) is ranked lower than
88% of the 189 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.10 vs. EXAS: -65.97 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
EXAS' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -74.53  Med: 0.00 Max: 41.6
Current: -65.97
-74.53
41.6

More Statistics

Revenue(Mil) $27
EPS $ -1.68
Beta-0.20
Short Percentage of Float34.19%
52-Week Range $5.37 - 32.85
Shares Outstanding(Mil)96.34

Analyst Estimate

Dec15 Dec16 Dec17 Dec18
Revenue(Mil) 42 96 167 243
EPS($) -1.76 -1.86 -1.58 -1.08
EPS without NRI($) -1.76 -1.86 -1.58 -1.08

Latest Earnings Webcast

» More Conference Calls

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:EXK.Germany,
Exact Sciences Corp was incorporated in the State of Delaware on February 10, 1995. The company is a molecular diagnostics company focused on the early detection and prevention of colorectal cancer. The Company's Cologuard test is designed to detect pre-cancerous lesions or polyps, and each of the four stages of colorectal cancer and is expected to be a powerful, preventive tool. By detecting pre-cancers and cancers early with its test, affected patients can be referred to colonoscopy, during which the polyps or lesions can be removed. In November 2012, Company completed enrollment for its pivotal FDA clinical trial with over 10,000 patients enrolled at 90 enrollment sites in the U.S. and Canada. All patients provided a sample to be tested with Cologuard test, and received a FIT test and a colonoscopy. As of December 31, 2013, Company owned 10 issued patents and 28 pending patent applications in the United States, and 62 issued patents and 26 pending patent applications in foreign jurisdictions. In addition, as part of its 2009 strategic transaction with Genzyme Corporation, it received an exclusive license back from Genzyme Corporation in the fields of colorectal cancer screening and stool-based detection of any disease or condition to the 26 patents issued and 7 pending patent applications in the U.S., and 29 patents issued and 12 pending patent applications in foreign jurisdictions sold to Genzyme. Certain of its activities are subject to regulatory oversight by the FDA under provisions of the Federal Food, Drug, and Cosmetic Act and regulations thereunder, including regulations governing the development, marketing, labeling, promotion, manufacturing and export of diagnostic products. sDNA testing faces competition from procedure-based detection technologies such as flexible sigmoidoscopy, colonoscopy and virtual colonoscopy.
» More Articles for EXAS

Headlines

Articles On GuruFocus.com
Whitney Tilson's Robin Hood Conference Presentation Nov 19 2015 
Why I'm Short Exact Sciences - Whitney Tilson Presentation Feb 24 2015 
Weekly CEO Sells Highlight: Exact Sciences Corp Zayo Group Holdings Inc, Western Alliance Bancorp, a Oct 27 2014 
Meridian Funds Comments on Exact Sciences Corp Jun 20 2014 
Weekly CEO Buys Highlight: BFS, FL, BGC, AMCF, and EXAS Nov 28 2010 
EXACT Sciences Corp. (EXAS) CEO Kevin T Conroy buys 6,000 Shares Nov 23 2010 
EXACT Sciences Corp. (EXAS) CFO Maneesh Arora buys 2,500 Shares Aug 20 2010 
Weekly CFO Buys Highlight: Heska Corp., Apollo Investment Corp., EXACT Sciences Corp., Innospec Inc. Feb 28 2010 

More From Other Websites
Exact Sciences to host fourth-quarter, full-year 2015 results webcast and call Feb 09 2016
Finding Value in These Names -- Agilent Technologies, Exact Sciences, Thermo Fisher Scientific, and... Feb 08 2016
Humana sued over unpaid colorectal cancer screenings Feb 05 2016
Exact Sciences to participate in Leerink Partners Global Healthcare Conference Feb 01 2016
Exact Sciences to participate in Leerink Partners Global Healthcare Conference Feb 01 2016
EXACT SCIENCES CORP Files SEC form 8-K, Change in Directors or Principal Officers Jan 27 2016
Exact Sciences announces appointment of John A. Fallon, M.D., to company's board of directors Jan 25 2016
Exact Sciences announces appointment of John A. Fallon, M.D., to company's board of directors Jan 25 2016
Battered American Eagle Outfitters (AEO), Plus 2 Other Companies Witness Insider Buying Jan 14 2016
Exact Sciences Announces Contract with Anthem BlueCross of California Jan 11 2016
Exact Sciences Announces Preliminary Fourth Quarter and Full Year 2015 Results Jan 11 2016
Exact Sciences Announces Contract with Anthem BlueCross of California Jan 11 2016
New Modeling Supports Using Cologuard® Every Three Years Jan 11 2016
Exact Sciences Announces Preliminary Fourth Quarter and Full Year 2015 Results Jan 11 2016
EXACT Sciences Corp. – Value Analysis (NASDAQ:EXAS) : January 6, 2016 Jan 06 2016
EXACT Sciences Corp. breached its 50 day moving average in a Bearish Manner : January 5, 2016 Jan 05 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK